CDXC: Small Float Biopharma with BIG Potential $20
After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.
It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.
It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.